Guselkumab

Guselkumab for psoriatic arthritis led to major improvements in joint disease activity, complete skin clearance and other “stringent” endpoints that were maintained through 2 years, according to data published in Clinical Rheumatology.

WASHINGTON — In patients with active Crohn’s disease, guselkumab was superior to both placebo and standard-of-care ustekinumab after 48 weeks of treatment, according to late-breaking data from the phase 3 GALAXI program.

Patients with psoriatic arthritis who use guselkumab are more likely to experience meaningful improvements in fatigue and pain if they achieve resolution of enthesitis or dactylitis, according to data published in Clinical Rheumatology.

Patients with active psoriatic arthritis who receive guselkumab demonstrate reduced work impairment, improved overall health and “substantial cost savings” through 2 years, according to data published in Rheumatology and Therapy.

In this Healio exclusive video, Raj Chovatiya, MD, PhD, discussed research into the interleukin-23 inhibitor guselkumab from the Maui Derm 2024 meeting.

Guselkumab demonstrates consistent pharmacological effects across both patients naïve to biologics and those with an inadequate response to TNF inhibitors, according data published in Arthritis & Rheumatology.

Patients with plaque psoriasis experienced greater efficacy with guselkumab compared with fumaric acid esters, according to a study.

Among patients with psoriatic arthritis treated with guselkumab, early joint improvement by week 8 predicts lower radiographic progression rates through 2 years, according to data published in Clinical Rheumatology.

In patients with psoriatic arthritis and an inadequate response to TNF inhibitors, guselkumab reduces levels of effector cytokines linked to arthritis and skin disease activity, according to data published in Arthritis Research & Therapy.

VANCOUVER, British Columbia — More than 50% of patients with Crohn’s disease who did not achieve clinical response at week 12 to IV Tremfya achieved response at week 48 after continuing subcutaneous therapy, according to a presenter.